

Acute Myeloid Leukemia

**A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission**

**Trial Status**  
Terminated

**Trial Runs In**  
5 Countries

**Trial Identifier**  
NCT03850535 2018-002964-25  
GO40800

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This Phase Ib/II, open-label, multicenter, non-randomized study will evaluate the safety, efficacy, and pharmacokinetics of idasanutlin when it is given in combination with cytarabine and daunorubicin in induction, in combination with cytarabine in consolidation, and as a single agent in maintenance for treating participants with acute myeloid leukemia (AML).

**Hoffmann-La Roche**  
Sponsor

**Phase 1/Phase 2**  
Phase

---

**NCT03850535 2018-002964-25 GO40800**  
Trial Identifiers

---

***Eligibility Criteria:***

**Gender**  
All

**Age**  
>=18 Years

**Healthy Volunteers**  
No

---